In a recent interview with Jim Cramer at CNBC, Johnson & Johnson's Chairman and CEO Joaquin Duato highlighted Impella™ heart pumps as one example of the transformational technologies that Johnson & Johnson MedTech offers to our customers and patients. You can learn more about Impella here: https://lnkd.in/ewy6PMkH
Tackling the world’s toughest health challenges as Chairman and Chief Executive Officer of Johnson & Johnson
Johnson & Johnson aims for transformational innovation, not just incremental gains. When Jim Cramer at CNBC asked me about the impact of our innovations, one of the examples I shared was the long-term survival benefits we are seeing with one of our heart recovery innovations. Impella®, the world’s smallest heart pumps, are inserted into the heart temporarily taking over its pumping function after a heart attack – allowing the heart to rest and recover. In a published clinical study of patients with cardiogenic shock, when compared to the control arm at 10 years, Impella® CP patients gained an average of 600 additional days alive. That’s what we mean when we say transformational innovation!
Love this company!
Sales at DePuy Orthopaedics
1wI2Pure will change OR protocol AND change the world